Golden
Novartis

Novartis

Novartis is a healthcare and pharmaceutical company based in Basel, Switzerland, incorporated in 1996.

Novartis products include oncology medicines, generic and biosimilar medicines and eye car devices. The Innovative Medicine segment of the company is divided into Novartis Oncology and Novartis Pharmaceuticals. Novartis Pharmaceuticals consists of global business franchises in ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines. 



Sandoz is a division of Novartis that manufactures, distributes and sells prescription medicines and pharmaceutical active substances that are not patent protected and is franchised into Retail generics, Anti-Infectives and Biopharmaceuticals. 



Alcon is a division of Novartis in the eye car product field in eye care devices and vision care. Alcon’s surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery and intraocular lenses to treat cataracts and refractive errors. Alcon’s Vision Care franchise includes contact lenses and contact lens care products. Alcon’s surgical portfolio also includes equipment for performing cataract surgery. 



Novartis, previously called Ciba-Geigy, was one of the few pharmaceutical companies involved in tyrosine kinase inhibitor research when it began a collaboration with oncologist Brian Druker which resulted in discovery of the kinase inhibitor drug Gleevec (also known as Glivec or imatinib). Gleevec was FDA approved in 2001 to treat patients with chronic myelogenous leukemia (CML). Kinases perform phosphorylation, a mechanism that controls the activity of proteins in the cell. CML patients have a mutation causing their tyrosine kinase to be overactive, which signals cell to proliferate at a high rate, resulting in accumulation of immature white blood cells. Based on revenue, Gleevec was one of Novartis’s top ten pharmaceutical products in 2017.



Novartis Oncology drug Kisqali (ribociclib) in Phase III MONALEESA (Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety) trials, was reported in December 2018 to demonstrate efficacy and tolerability in combination with endocrine therapy in advanced breast cancer patients with visceral involvement. Kisqali (ribociclib) is a cyclin-dependent kinase inhibitor that inhibits cyclin-dependent kinase 4 and 6 (CDK4/6), proteins that when over active can promote cancer cell division and cancer growth. The drug is an orally available small molecule that acts by blocking phosphorylation of the retinoblastoma protein, which prevents cell-cycle progression. Kisqali is also in the NATALEE study, a Phase III clinical trial with endocrine therapy to treat early breast cancer.





Timeline

October 1, 2019

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence.



April 1, 2019

Novartis agrees to pay $310 million, with the possibility for more later, for some assets of Boston-based IFM Therapeutics.

2010

Novartis bought Alcon's eye surgery and contact lens portfolio in stages through 2010 for $52 billion from Nestle.

People

Name
Role
LinkedIn

Barry X Lynn

Investor



Chris Ilsley

President, Chief Executive Officer



Enrico Vanni

Independent Non-Executive Vice Chairman of the Board



Harry Kirsch

Chief Financial Officer, Member of the Executive Committee



Joerg Reinhardt

Independent Non-Executive Chairman of the Board



Ken Londoner

Advisor



Mike Ryan

Investor



prakash thombre

Investor



Stacia Danielle Sullivan

Founder



Steven Zeppenfeld

Investor



V and K Law

Attorney



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









News

Title
Author
Date
Publisher
Description
John Miller
January 29, 2020
IN
Novartis boss Vas Narasimhan expects higher sales and profitability this year, lifted by its broad range of drugs, and minimal disruption to its supply chain from the coronavirus outbreak in China.
Reuters Editorial
January 29, 2020
IN
Novartis's fourth-quarter core net income rose 13% in constant currencies, helped as its new Zolgensma gene therapy gained traction and five-year-old drugs Cosentyx and Entresto added to their blockbuster status.
John Miller
December 19, 2019
IN
Novartis aims to give away 100 doses of its $2.1 million-per-patient Zolgensma for spinal muscular atrophy (SMA) in 2020 in a free-drug programme that one patient group worried was a "health lottery" that could neglect some babies.
Sohini Das
December 11, 2019
@bsindia
Read more about Huge relief for cardio-diabetic patients as three key drugs go off patent on Business Standard. The prices have already dropped by almost 80% in most cases.
Gina Kolata
December 7, 2019
www.nytimes.com
Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life.
December 5, 2019
news.yahoo.com
Novartis strikes a multiyear deal with AWS to leverage artificial intelligence and data analytics to revamp the steps involved in drug manufacturing.
Lydia Ramsey
December 3, 2019
Business Insider
From enhancing drug discovery to building tools for employees, here are the priorities of the chief digital officers at Pfizer, CVS, and Novartis.
Sarah Neville
November 28, 2019
Financial Times
Carl O'Donnell
November 27, 2019
U.S.
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.
Silke Koltrowitz
November 25, 2019
IN
Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc , Sanofi and Regeneron Pharmaceuticals .
The Associated Press
November 24, 2019
www.nytimes.com
The Medicines Company focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower so-called bad cholesterol.
Reuters Editorial
November 18, 2019
IN
Novartis is halting early-stage research in Shanghai and shifting the site's focus to commercial development three years after the Swiss drugmaker christened the new $1 billion campus as its Chinese drug discovery hub.
November 16, 2019
NDTV.com
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
Reuters Editorial
November 11, 2019
IN
Novartis is buying the Japanese generics unit of South Africa's Aspen Pharmacare in a deal worth up to 400 million euros ($440.80 million) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday.
Sohini Das
October 8, 2019
@bsindia
Read more about Price of key diabetes drug may crash as Novartis risks losing patent on Business Standard. A look at the top 10 brands of Novartis in India shows that mature brands like Voveran and Calcium Sandoz are clocking low single-digit growth
Lydia Ramsey
October 4, 2019
Business Insider
Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
October 1, 2019
WebWire
, , , , • Multiyear alliance underpins the Novartis commitment to leverage data & artificial intelligence (AI) to transform how medicines are discovered, developed and commercialized , , • Novartis to establish AI innovation lab to empower its associates to use AI across the business , , • Joint research activities will include co-working environments on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) - starting with tackling person...
Emma Court and Clarrie Feinstein
September 27, 2019
Business Insider
Since an analysis from Jefferies was released, three of the companies it tapped have said that they plan to go public.
Emma Court
September 24, 2019
Business Insider
Novartis blames two brothers who were execs at its AveXis unit. Because of that, the company says it initially led a secret investigation.
September 10, 2019
WebWire
, , , , • Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent ® (siponimod) and Gilenya ® (fingolimod) , , , , • Results from head-to-head Phase III ASCLEPIOS studies evaluating efficacy and safety of ofatumumab, an investigational B-cell therapy that potentially can be administered subcutaneously at home by patients with relapsing multiple s...
SHOW MORE

References